Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Paris  >  Valneva SE    VLA   FR0004056851

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

VIVALIS : MISE A DISPOSITION DU DOCUMENT DE REFERENCE 2011

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/27/2012 | 07:35am CEST

VIVALIS PUBLIE SON
DOCUMENT DE REFERENCE 2011

Nantes, Lyon (France) - 27 avril 2012 : VIVALIS (NYSE Euronext Paris : VLS), société biopharmaceutique, annonce que son Document de référence 2011 a été déposé le 25 avril 2012 auprès de l'Autorité des Marchés Financiers (AMF) sous le numéro D12-0412.

Des exemplaires du présent Document de Référence sont disponibles sans frais auprès de la Société, au 6, rue Alain Bombard, 44821 Saint-Herblain cedex, ainsi qu'en version électronique sur le site internet de la Société (www.vivalis.com) et  sur le site internet de l'Autorité des marchés financiers (www.amf-france.org:
http://www.amf-france.org/).

Les documents suivants sont notamment intégrés dans le document de référence 2011 :
-       le rapport financier annuel,
-       le rapport du Président du Conseil de surveillance sur les conditions d'organisation et de préparation des travaux du Conseil de surveillance et sur les procédures de contrôle interne mises en place par la Société,
-       les informations relatives aux honoraires versés aux commissaires aux comptes,
-       le document d'information annuel.

VIVALIS MISE A DISPOSITION DU DOCUMENT DE REFERENCE:
http://hugin.info/143334/R/1606613/509370.pdf



This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.

Source: VIVALIS via Thomson Reuters ONE

HUG#1606613
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on VALNEVA SE
04/19 VALNEVA : Announces Signing of a New EB66 Commercial License with Bavarian Nordi..
04/19 VALNEVA : Reinhard Kandera Appointed Chief Financial Officer of Hookipa Biotech
04/18 VALNEVA : Announces Signing of a New EB66® Commercial License with Bavarian Nord..
04/18 VALNEVA : Announces Signing of a New EB66® Commercial License with Bavarian Nord..
04/10 VALNEVA : to Present at the 17th World Vaccine Congress in Washington D.C.
03/23 VALNEVA : Reports Best FY Results in the Company’s History with its First ..
03/23 VALNEVA : Reports Best Financial Results in the Company's History with its First..
03/23 VALNEVA : Announces Publication of its Registration Document
03/20VALNEVA SE : annual earnings release
02/23 VALNEVA : Reports Strong Q4 and FY 2016 Business Performance; Expects Further Gr..
More news
Sector news : Biotechnology & Medical Research - NEC
04/28 REGENERON PHARMACEUTICALS : Sanofi beats profit forecasts, upbeat on prospects f..
04/28DJSanofi 1st-Quarter Net Profit Rises on Sale of Animal-Health Unit
04/27 AMGEN : Cost controls help offset lower Amgen first-quarter drug sales
04/26 New GlaxoSmithKline CEO wants fewer, bigger new drug launches
04/18 Johnson & Johnson first quarter revenue misses estimates; new forecast includ..
More sector news : Biotechnology & Medical Research - NEC
Advertisement
Financials (€)
Sales 2017 116 M
EBIT 2017 1,73 M
Net income 2017 2,65 M
Debt 2017 56,2 M
Yield 2017 -
P/E ratio 2017 36,67
P/E ratio 2018 42,31
EV / Sales 2017 2,32x
EV / Sales 2018 2,04x
Capitalization 213 M
More Financials
Chart VALNEVA SE
Duration : Period :
Valneva SE Technical Analysis Chart | VLA | FR0004056851 | 4-Traders
Full-screen chart
Technical analysis trends VALNEVA SE
Short TermMid-TermLong Term
TrendsBullishBearishNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Average target price 4,51 €
Spread / Average Target 64%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Thomas Lingelbach President & Chief Executive Officer
Frédéric Grimaud Chairman-Supervisory Board
Reinhard Kandera Chief Financial Officer
Klaus Schwamborn Vice President-Discovery Research & Innovation
James R. Sulat Vice Chairman-Supervisory Board
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
VALNEVA SE-13.27%232
INCYTE CORPORATION23.95%25 426
QUINTILES IMS HOLDINGS..10.82%19 884
LONZA GROUP AG17.13%11 836
SEATTLE GENETICS, INC.29.43%9 741
CELLTRION, INC.--.--%9 653
More Results